TIMOTHY A. SPRINGER - 09 Apr 2025 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)

Signature
/s/ Matthew Bartholomae, Attorney-in-Fact for Timothy A. Springer
Issuer symbol
RNAC
Transactions as of
09 Apr 2025
Net transactions value
+$1,522,517
Form type
4
Filing time
11 Apr 2025, 17:29:40 UTC
Previous filing
09 Apr 2025
Next filing
11 Jun 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNAC Common Stock Purchase $69,209 +7,342 +0.09% $9.43 8,628,667 09 Apr 2025 Direct F1
transaction RNAC Common Stock Purchase $308 +31 +0% $9.95 8,628,698 09 Apr 2025 Direct F2
transaction RNAC Common Stock Purchase $392,176 +41,604 +7.9% $9.43 571,402 09 Apr 2025 See Footnote F1, F3
transaction RNAC Common Stock Purchase $1,771 +178 +0.03% $9.95 571,580 09 Apr 2025 See Footnote F2, F3
transaction RNAC Common Stock Purchase $83,121 +7,966 +0.09% $10.43 8,636,664 10 Apr 2025 Direct F4
transaction RNAC Common Stock Purchase $6,652 +609 +0.01% $10.92 8,637,273 10 Apr 2025 Direct
transaction RNAC Common Stock Purchase $471,055 +45,144 +7.9% $10.43 616,724 10 Apr 2025 See Footnote F3, F4
transaction RNAC Common Stock Purchase $37,696 +3,451 +0.56% $10.92 620,175 10 Apr 2025 See Footnote F3
transaction RNAC Common Stock Purchase $69,074 +6,412 +0.07% $10.77 8,643,685 11 Apr 2025 Direct F5
transaction RNAC Common Stock Purchase $391,455 +36,338 +5.9% $10.77 656,513 11 Apr 2025 See Footnote F3, F5
holding RNAC Common Stock 330,695 09 Apr 2025 By wife
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $8.95 to $9.91. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $9.95 to $9.97. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3 Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.
F4 The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $9.918 to $10.7461. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F5 The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $10.395 to $11.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.